Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded access Sarconeos (BIO101)

Next Previous
Trial Profile

Expanded access Sarconeos (BIO101)

Status: Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 01 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sarconeos (Primary)
  • Indications SARS-CoV-2 acute respiratory disease
  • Focus Expanded access; Therapeutic Use
  • Sponsors Biophytis

Most Recent Events

  • 30 Oct 2023 According to a Biophytis media release, this program will enable a maximum of 80 patients suffering from critical forms of COVID-19 to be treated for 28 days under mechanical ventilation in the intensive care units of Brazilian hospitals.
  • 30 Oct 2023 According to a Biophytis media release, company announces the signature of a partnership with Innovation Solutions Pharma, who will represent Biophytis in front of the Brazilian agency ANVISA to lift the suspension of the Early Access Program (EAP) authorized at the beginning of 2022.
  • 30 Oct 2023 According to a Biophytis media release, company aims to start this early access program in Brazil in the first quarter of 2024, and to continue expanding early access program in France and in other countries.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top